Pharmacologically active antiviral peptides

Details Pharmacologically active antiviral peptides Pharmacologically active antiviral peptides

2001-02-06

2008-05-13

Chen, Stacy B. (Department: 1648)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

C424S185100

Reexamination Certificate

active

07371809

ABSTRACT:
This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.

REFERENCES:
patent: 4795740 (1989-01-01), Cohen et al.
patent: 5104854 (1992-04-01), Schlesinger et al.
patent: 5182265 (1993-01-01), Bruzzese et al.
patent: 5260420 (1993-11-01), Burnouf-Radosevich et al.
patent: 5380727 (1995-01-01), Déziel et al.
patent: 5441936 (1995-08-01), Houghten et al.
patent: 5645849 (1997-07-01), Pruss et al.
patent: 5700780 (1997-12-01), Beaulieu et al.
patent: 5877282 (1999-03-01), Nadler et al.
patent: 6635248 (2003-10-01), Ternynck et al.
patent: 0 531 080 (1993-03-01), None
patent: 2739621 (1997-04-01), None
patent: 4-21635 (1992-01-01), None
patent: WO 99/05302 (1999-02-01), None
patent: WO 99/64449 (1999-12-01), None
Walker et al. Nature 407:313-314, 2000.
Barouch et al. Nature 415:335-339, 2002.
Desrosiers, Nature Medicine, Mar. 2004, 10(3):221-223).
Feinberg et al. Nature Medicine, Mar. 2002, 8(3):207-210.
Richards et al., Journal of Virology, 2003, 77(12):6692-6699.
National Center for Infectious Diseases, Cytomegalovirus Infection (CMV), www.cdc.gov
cidod/diseases/cmv/htm website last updated Sep. 12, 2005, printout, pp. 1-5.
G. Wagner and J. Oehlke, “Mercaptopurin-Protein-Azokonjugate,”Pharmazie 32157-162, 1977.
R. V. Srinivas et al., “Antiviral Effects of Apolipoprotein A-I and Its Synthetic Amphipathic Peptide Analogs,”Virology 176, pp. 48-57, 1990.
S. K. Srinivas et al., “Membrane Interactions of Synthetic Peptides Corresponding to Amphipathic Helical Segments of the Human Immunodeficiency Virus Type-1 Envelope Glycoprotein,”J. Biol. Chem. 267(10), pp. 7121-7127, Apr. 1992.
C. Wild et al., “A Synthetic Peptide Inhibitor of Human Immunodeficiency Virus Replication: Correlation Between Solution Structure and Viral Inhibition,”Proc. Nat'l. Acad. Sci. USA 89, pp. 10537-10541, Nov. 1992.
D. Derossi et al., “The Third Helix of the Antennapedia Homeodomain Translocates Through Biological Membranes,”The Journal of Biological Chemistry 269(14), pp. 10444-10450, Apr. 1994.
C. Wild et al., “Peptides Corresponding to a Predictive α-Helical Domain of Human Immunodeficiency Virus Type 1 gp41 are Potent Inhibitors of Virus Infection,”Proc. Nat'l. Acad. Sci. USA 91, pp. 9770-9774, Oct. 1994.
C. Wild et al., “Propensity for a Leucine Zipper-Like Domain of Human Immunodeficiency Virus Type 1 gp41 to Form Oligomers Correlates with a Role in Virus-Induced Fusion Rather than Assembly of the Glycoprotein Complex,”Proc. Nat'l. Acad. Sci. USA 91, pp. 12676-12680, Dec. 1994.
J. Oehlke et al., “Utilization of Endothelial Cell Monolayers of Low Tightness for Estimation of Transcellular Transport Characteristics of Hydrophilic Compounds,”Euro. J. Pharm. 2, pp. 365-372, 1994.
Y-Z. Lin et al., “Inhibition of Nuclear Translocation of Transcription Factor NF-κB by a Synthetic Peptide Containing a Cell Membrane-Permeable Motif and Nuclear Localization Sequence,,”The Journal of Biological Chemistry 270(24), pp. 14255-14258, Jun. 1995.
J. Brugidou et al., “TheRetro InversoForm of a Homeobox-Derived Short Peptide is Rapidly Internalized by Cultured Neurones: A New Basis for an Efficient Intracellular Delivery System,”Biochemical and Biophysical Research Communications 214(2), pp. 685-693, Sep. 1995.
D. Derossi, “Antennapedia Homeodomain Third Helix as a Peptide and Oligonucleotide Vector,”Restorative Neurology and Neuroscience 8, pp. 17-18, 1995.
S. Rothemund et al., “Recognition of α-Helical Peptide Structures Using High-Performance Liquid Chromatographic Retention Data for D-Amino Acid Analogues: Influence of Peptide Amphipathicity and of a Stationary Phase Hydrophobicity,”Journal of Chromatography A 689, pp. 219-226, 1995.
C. Brandt et al., “Evaluation of a Peptidomimetic Ribonucleotide Reductase Inhibitor with a Murine Model of Herpes Simplex Virus Type 1 Ocular Disease,”Antimicrobial Agents and Chemotherapy 40(5), pp. 1078-1084, May 1996.
D. Derossi et al., “Cell Internalization of the Third Helix of the Antennapedia Homeodomain is Receptor-Independent,”The Journal of Biological Chemistry 271(30), pp. 18188-18193, Jul. 1996.
E. Krause et al., “Conformation of a Water-Soluble β-Sheet Model Peptide,”Int. J. Peptide Protein Res. 48, pp. 559-568, 1996.
J. Oehlke et al., “Nonendocytic, Amphipathicity Dependent Cellular Uptake of Helical Model Peptides,”Protein and Peptide Letters 3(6), pp. 393-398, 1996.
Q. Yao and R. W. Compans, Peptides Corresponding to the Heptad Repeat Sequence of Human Parainfluenza Virus Fusion Protein are Potent Inhibitors of Virus Infection,Virology 223, pp. 103-112, 1996.
G. Elliott and P. O'Hare, “Intercellular Trafficking and Protein Delivery by a Herpesvirus Structural Protein,”Cell 88, pp. 223-233, Jan. 1997.
C. Yang and R. W. Compans, Analysis of the Murine Leukemia Virus R Peptide: Delineation of the Molecular Determinants Which are Important for Its Fusion Inhibition Activity,Journal of Virology 71(11), pp. 8490-8496, Nov. 1997.
J. Oehlke et al., “Extensive Cellular Uptake into Endothelial Cells of an Amphipathic β-Sheet Forming Peptide,”Federation of European Biochemical Societies Letter 415, 196-199, 1997.
L. T. Rimsky et al., “Determinants of Human Immunodeficiency Virus Type 1 Resistance gp41-Derived Inhibitory Peptides,”Journal of Virology 72(2), pp. 986-993, Feb. 1998.
M. Rojas et al., “Genetic Engineering of Proteins with Cell Membrane Permeability,”Nature Biotechnology 16, pp. 370-375, Apr. 1998.
A. Phelan et al., “Intercellular Delivery of Functional p53 by the Herpesvirus Protein VP22,”Nature Biotechnology 16, pp. 440-443, May 1998.
S. Y. Hong et al., “Identification and Characterization of Novel Antimicrobial Decapeptides Generated by Combinatorial Chemistry,”Antimicrobial Agents and Chemotherapy 42(10), pp. 2534-2541, Oct. 1998.
J. M. Kilby et al., “Potent Suppression of HIV-1 Replication in Humans by T-20, a Peptide Inhibitor of gp41-Mediated Virus Entry,”Nature Medicine 4(11), pp. 1302-1307, Nov. 1998.
G. Aldrian-Herrada e al., “A Peptide Nucleic Acid (PNA) is More Rapidly Internalized in Cultured Neurons when Coupled to aretro-inversoDelivery Peptide. The Antisense Activity Depresses the Target mRNA and Protein in Magnocellular Oxytocin Neurons,”Nucleic Acids Research 26(21), pp. 4910-4916, 1998.
B. Böttcher et al., “Peptides that Block Hepatitis B Virus Assembly: Analysis by Cryomicroscopy, Mutagenesis and Transfection,”The EMBO Journal 17(23), pp. 6839-6845, 1998.
C. Du et al., “Conformational and Topological Requirements of Cell-Permeable Peptide Function,”J. Peptide Res. 51, pp. 235-243, (1998).
W. A. O'Brien, et al., “Anti-Human Immunodeficiency Virus Type 1 Activity of an Oligocationic Compound Mediated via gp120 V3 Interactions,”Journal of Virology, vol. 70, No. 5, pp. 2825-2831, 1996, published by the American Society for Microbiology.
I. Choudhury, et al., “Inhibition of HIV-1 Replication by a Tat RNA-Binding Domain Peptide Analog,”Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol. 17, No. 2, pp. 104-111, Feb. 1, 1998, published by Lippincon-Raven Publishers, Philadelphia.
M. Pooga, et al., “Cell penetration by transportan,”FASEB Journal, vol. 12, pp. 67-77, Jan. 1998, published by the Federation for American Societies for Experimental Biology.
J. Oehlke, et al., “Cellular uptake of an α-helical amphipathic model peptide with the potential to deliver po

Affiliated with

Also associated with

Rating

Pharmacologically active antiviral peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmacologically active antiviral peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmacologically active antiviral peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3985527